Family medicine clinicians are positioned at the front line of obesity management and will face increasing patient demand as oral GLP-1 options like orforglipron expand market accessibility beyond the injectable segment. Cost barriers have historically driven high discontinuation rates and inequitable access, meaning clinicians must be prepared to navigate formulary restrictions, prior authorization burdens, and patient financial assistance programs as part of routine metabolic care. The rapid early uptake of Lilly’s oral agent signals that primary care panels will absorb a substantial volume of new GLP-1 initiations, requiring familiarity with the distinct pharmacokinetic and dosing considerations of oral versus injectable formulations.
Eli Lilly’s chief executive has indicated that GLP-1 and related obesity pharmacotherapies are projected to reach approximately 50 percent of their eligible patient population at peak market penetration, a figure that reflects persistent structural barriers to access rather than limitations in clinical demand or therapeutic efficacy. The primary driver constraining uptake remains cost, with obesity medications continuing to price out a substantial portion of patients who meet clinical criteria for treatment. This dynamic has direct implications for prescribers managing patients with obesity-related comorbidities, as a meaningful share of the population that would benefit from pharmacotherapy will remain undertreated under current pricing and coverage conditions.
The report also highlights early commercial traction for Foundayo, Lilly’s oral GLP-1 formulation, which generated hundreds of prescriptions within its first week of availability. While week-one prescription volume is an early and inherently limited metric, the uptake suggests meaningful prescriber interest in an oral route of administration, which may address one of the documented barriers to initiating injectable GLP-1 therapy in certain patient populations. For clinicians, the availability of an oral agent in this class expands the practical toolkit for metabolic and weight management, particularly for patients with needle aversion or those earlier in the treatment decision process. The combination of projected long-term access limitations at the population level alongside growing formulation options at the clinical level underscores the dual challenge prescribers face: identifying appropriate candidates for therapy while navigating the real-world constraints that determine who can actually sustain treatment.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →GLP-1 and obesity medications continue to face significant access barriers, with cost remaining one of the most commonly cited reasons patients do not initiate or sustain therapy. Despite growing clinical demand, a substantial portion of eligible patients may never reach treatment at peak market penetration, according to industry projections. The recent launch of Lilly’s oral GLP-1 option, Foundayo, generated notable early prescribing activity, suggesting patient and clinician appetite for more convenient formulations. In practice, family medicine providers should proactively screen patients for insurance coverage and out-of-pocket cost concerns at the point of prescribing, and be prepared to discuss patient assistance programs or formulary alternatives to prevent cost-related discontinuation before meaningful clinical benefit is achieved.
“The reality that only about half of potential users may ever access these medications at peak penetration is not just a market projection – it is a clinical failure we should all be paying attention to. Cost remains one of the most underappreciated barriers in obesity medicine, and when a patient cannot afford the therapy we know would benefit them, that gap lands squarely on the prescribing clinician to address with alternatives, bridges, and advocacy. The early uptake of Foundayo is encouraging as an oral option that may shift some of the access equation, particularly for patients who face both cost and injection barriers. In practice, this means every obesity medicine conversation needs to include a frank discussion about affordability and realistic access pathways before we build a treatment plan around a medication the patient may never be able to fill.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What are GLP-1 weight-loss drugs and how do they work?
- Why can’t everyone who wants a GLP-1 medication get one?
- What is Foundayo and how is it different from injectable GLP-1 drugs?
- Is a GLP-1 pill as effective as an injectable version?
- Who is a good candidate for GLP-1 therapy?
- Will my insurance cover a GLP-1 medication for weight loss?
- What are the most common side effects of GLP-1 medications?
- How long do I need to stay on a GLP-1 medication to maintain my results?
- Are GLP-1 medications safe for people with heart disease?
- What should I do if I cannot afford my GLP-1 prescription?
- Read next
FAQ
What are GLP-1 weight-loss drugs and how do they work?
GLP-1 medications are a class of drugs that mimic a hormone your body naturally produces after eating, which helps regulate blood sugar and reduce appetite. They work by slowing digestion, increasing feelings of fullness, and reducing cravings. This combination leads to meaningful weight loss in most patients who use them consistently.
Why can’t everyone who wants a GLP-1 medication get one?
The biggest barrier right now is cost, as many insurance plans do not cover these medications for weight loss and the out-of-pocket price can be several hundred to over a thousand dollars per month. Even patients who qualify medically may find the expense unsustainable long-term. This is why healthcare leaders and manufacturers are working on lower-cost options, including pill forms of these therapies.
What is Foundayo and how is it different from injectable GLP-1 drugs?
Foundayo is an oral GLP-1 medication made by Eli Lilly that was recently approved, offering patients a pill option rather than a weekly injection. This is significant because many patients prefer not to self-inject, and a pill form may improve access and adherence. Early prescription data suggests strong patient and provider interest in this new formulation.
Is a GLP-1 pill as effective as an injectable version?
Clinical trials for oral GLP-1 agents have shown meaningful weight loss, though results can vary compared to injectable formulations depending on the specific drug and dose. Your physician will help determine which form is most appropriate based on your health history and goals. Both routes of administration require consistent use and lifestyle changes to achieve the best outcomes.
Who is a good candidate for GLP-1 therapy?
GLP-1 medications are generally indicated for adults with obesity, defined as a body mass index of 30 or higher, or for those with a BMI of 27 or higher who also have a weight-related condition such as type 2 diabetes or high blood pressure. Your doctor will evaluate your full medical history before recommending this type of treatment. These drugs are not appropriate for everyone, and a thorough clinical assessment is an essential first step.
Will my insurance cover a GLP-1 medication for weight loss?
Coverage varies widely depending on your specific insurance plan, employer, and state regulations, and many plans still do not cover GLP-1 drugs when prescribed solely for weight management. Coverage is more commonly available when the medication is prescribed for type 2 diabetes. Speaking with your doctor’s office and your insurance provider directly is the best way to understand your individual benefits.
What are the most common side effects of GLP-1 medications?
The most frequently reported side effects include nausea, vomiting, diarrhea, and constipation, particularly when starting the medication or increasing the dose. These symptoms often improve over time as your body adjusts to the treatment. Your physician may use a gradual dose escalation schedule to help minimize discomfort.
How long do I need to stay on a GLP-1 medication to maintain my results?
Current evidence suggests that weight regain is common when GLP-1 therapy is discontinued, which means many patients benefit from long-term or indefinite use to sustain their results. This is similar to how other chronic conditions like high blood pressure require ongoing treatment. Your physician will help you weigh the benefits and costs of continued therapy based on your individual response and health status.
Are GLP-1 medications safe for people with heart disease?
Several GLP-1 receptor agonists have demonstrated cardiovascular benefits in large clinical trials, including reductions in heart attack and stroke risk in patients with established cardiovascular disease. This makes them a particularly compelling option for patients managing both obesity and heart health concerns. Always inform your prescribing physician about your full cardiac history so the safest and most effective option can be selected.
What should I do if I cannot afford my GLP-1 prescription?
Pharmaceutical manufacturers often offer savings programs or patient assistance programs that can significantly reduce out-of-pocket costs for eligible patients. Your physician’s office or a pharmacist can help you identify these programs or explore whether a different formulation or alternative medication fits your budget. Telehealth platforms and specialty obesity medicine clinics may also have resources to help navigate access barriers.
